S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
US Dollar Replaced By "Biden Bucks"? (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
US Dollar Replaced By "Biden Bucks"? (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
US Dollar Replaced By "Biden Bucks"? (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
US Dollar Replaced By "Biden Bucks"? (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
US Dollar Replaced By "Biden Bucks"? (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
US Dollar Replaced By "Biden Bucks"? (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
US Dollar Replaced By "Biden Bucks"? (Ad)
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
US Dollar Replaced By "Biden Bucks"? (Ad)
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
New climate deal spurs hopes of more carbon storage projects
The Financial Day of Reckoning Has Begun (Ad)
OTCMKTS:AMAR

Amarillo Biosciences - AMAR Competitors

$0.60
-0.10 (-14.27%)
(As of 05/21/2021)
Add
Compare
Today's Range
$0.60
$0.70
50-Day Range
$0.21
$3.24
52-Week Range
$0.05
$1.97
Volume
6,100 shs
Average Volume
18,253 shs
Market Capitalization
$25.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

AMAR vs. ATNX, NBTX, ATNM, VIRX, IFRX, ATOS, NXTC, EPIX, SESN, and CRMD

Should you be buying Amarillo Biosciences stock or one of its competitors? The main competitors of Amarillo Biosciences include Athenex (ATNX), Nanobiotix (NBTX), Actinium Pharmaceuticals (ATNM), Viracta Therapeutics (VIRX), InflaRx (IFRX), Atossa Therapeutics (ATOS), NextCure (NXTC), ESSA Pharma (EPIX), Sesen Bio (SESN), and CorMedix (CRMD). These companies are all part of the "pharmaceutical preparations" industry.

Amarillo Biosciences vs.

Athenex (NASDAQ:ATNX) and Amarillo Biosciences (OTCMKTS:AMAR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Athenex has a net margin of -160.39% compared to Amarillo Biosciences' net margin of -41,453.98%. Amarillo Biosciences' return on equity of 0.00% beat Athenex's return on equity.

Company Net Margins Return on Equity Return on Assets
Athenex -160.39% -258.81% -43.21%
Amarillo Biosciences -41,453.98% N/A -574.29%

Athenex currently has a consensus price target of $4.00, suggesting a potential upside of 645.99%. Given Athenex's higher possible upside, equities research analysts plainly believe Athenex is more favorable than Amarillo Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Athenex
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Amarillo Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

In the previous week, Athenex had 13 more articles in the media than Amarillo Biosciences. MarketBeat recorded 15 mentions for Athenex and 2 mentions for Amarillo Biosciences. Athenex's average media sentiment score of 0.67 beat Amarillo Biosciences' score of 0.00 indicating that Athenex is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Athenex
3 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Amarillo Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

40.9% of Athenex shares are owned by institutional investors. 12.0% of Athenex shares are owned by company insiders. Comparatively, 34.4% of Amarillo Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Athenex received 231 more outperform votes than Amarillo Biosciences when rated by MarketBeat users. However, 68.13% of users gave Amarillo Biosciences an outperform vote while only 65.84% of users gave Athenex an outperform vote.

CompanyUnderperformOutperform
AthenexOutperform Votes
293
65.84%
Underperform Votes
152
34.16%
Amarillo BiosciencesOutperform Votes
62
68.13%
Underperform Votes
29
31.87%

Athenex has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Amarillo Biosciences has a beta of -0.06, meaning that its share price is 106% less volatile than the S&P 500.

Amarillo Biosciences has lower revenue, but higher earnings than Athenex.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Athenex$120.18 million0.54-$199.77 million-$1.72-0.31
Amarillo Biosciences$20 thousand1,262.19-$1.45 millionN/AN/A

Summary

Athenex beats Amarillo Biosciences on 10 of the 15 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of OTCMKTS and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMAR vs. The Competition

MetricAmarillo BiosciencesPharmaceutical IndustryMedical SectorOTCMKTS Exchange
Market Cap$25.24M$5.63B$4.41B$6.48B
Dividend YieldN/A2.41%7.26%35.51%
P/E RatioN/A10.66123.551.85
Price / Sales1,262.19468.132,950.751,206.27
Price / CashN/A21.8222.8919.99
Price / Book-20.008.656.466.03
Net Income-$1.45M$187.51M$166.90M$726.41M
7 Day Performance-16.65%5.67%4.70%1.81%
1 Month Performance-14.27%11.47%10.80%6.27%
1 Year PerformanceN/A-31.64%-27.19%79.93%

Amarillo Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATNX
Athenex
2.4825 of 5 stars
$1.11
+0.9%
$4.00
+260.4%
-83.9%$134.99M$120.18M-0.65652Short Interest ↓
Gap Up
NBTX
Nanobiotix
1.4695 of 5 stars
$3.96
+2.1%
N/A-64.7%$137.91M$3.13M0.0098Positive News
ATNM
Actinium Pharmaceuticals
1.7 of 5 stars
$5.65
+4.4%
$31.67
+460.5%
N/A$134.39M$1.14M0.0032
VIRX
Viracta Therapeutics
2.5865 of 5 stars
$3.69
+6.3%
$21.00
+469.1%
-56.9%$138.33M$2.07M-2.9824Positive News
IFRX
InflaRx
1.979 of 5 stars
$3.14
+3.3%
$7.00
+122.9%
+12.4%$138.80MN/A-3.1455Short Interest ↑
ATOS
Atossa Therapeutics
0 of 5 stars
$1.05
+7.1%
N/A-64.6%$132.96MN/A-5.836Positive News
Gap Up
NXTC
NextCure
2.3684 of 5 stars
$5.04
+3.1%
$15.00
+197.6%
-28.0%$139.85M$22.38M-1.9087
EPIX
ESSA Pharma
2.3978 of 5 stars
$3.01
+1.3%
$21.00
+597.7%
-74.8%$132.49MN/A-3.5025Analyst Revision
News Coverage
Positive News
SESN
Sesen Bio
1.4412 of 5 stars
$0.70
flat
$8.00
+1,037.7%
-65.4%$140.26M$26.54M2.8135
CRMD
CorMedix
1.9022 of 5 stars
$3.38
+5.6%
$13.00
+284.6%
N/A$132.24M$240,000.00-4.6329Earnings Report
High Trading Volume
This page (OTCMKTS:AMAR) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.